105 related articles for article (PubMed ID: 6496539)
1. High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma.
Shipp MA; Takvorian RC; Canellos GP
Am J Med; 1984 Nov; 77(5):845-50. PubMed ID: 6496539
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma.
Adelstein DJ; Lazarus HM; Hines JD; Herzig RH
Cancer; 1985 Oct; 56(7):1493-6. PubMed ID: 4027885
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytosine arabinoside in non-Hodgkin's lymphoma.
Kantarjian H; Barlogie B; Plunkett W; Velasquez W; McLaughlin P; Riggs S; Cabanillas F
J Clin Oncol; 1983 Nov; 1(11):689-94. PubMed ID: 6366130
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent.
Soiffer RJ; Caligiuri MA; Tondini C; Canellos GP
Cancer; 1989 Nov; 64(10):2014-8. PubMed ID: 2553238
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Wang WS; Tzeng CH; Chiou TJ; Liu JH; Hsieh RK; Yen CC; Chen PM
Jpn J Clin Oncol; 1997 Jun; 27(3):154-7. PubMed ID: 9255269
[TBL] [Abstract][Full Text] [Related]
6. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
[TBL] [Abstract][Full Text] [Related]
9. [Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas].
Domingo Albós A; Callís M; Juliá A; Vilá J; Zuazu J; Puig J; Petit J; Fernández-Sevilla A
Sangre (Barc); 1989 Apr; 34(2):107-11. PubMed ID: 2756450
[TBL] [Abstract][Full Text] [Related]
10. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
Shimazaki C; Fujita N; Nakanishi S; Nishio A; Haruyama H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion of high-dose cytosine arabinoside for treatment of childhood acute leukemia and non-Hodgkin's lymphoma in relapse.
Jones GR; Ettinger LJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):150-4. PubMed ID: 3874431
[No Abstract] [Full Text] [Related]
12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
13. Intermediate-dose cytosine arabinoside in the treatment of recurrent or refractory non-Hodgkin's lymphoma.
Takagi T; Sakai C; Oguro M
Jpn J Clin Oncol; 1989 Jun; 19(2):123-6. PubMed ID: 2733165
[TBL] [Abstract][Full Text] [Related]
14. The use of high-dose cytosine arabinoside for non-Hodgkin's lymphoma.
Richards MA; Barnett MJ; Waxman JH; Rohatiner AZ; Dhaliwal HS; Gallagher CJ; Lister TA
Semin Oncol; 1985 Jun; 12(2 Suppl 3):223-6. PubMed ID: 4012341
[No Abstract] [Full Text] [Related]
15. Cerebellar toxicity with high-dose cytosine arabinoside.
Herzig RH; Hines JD; Herzig GP; Wolff SN; Cassileth PA; Lazarus HM; Adelstein DJ; Brown RA; Coccia PF; Strandjord S
J Clin Oncol; 1987 Jun; 5(6):927-32. PubMed ID: 3585447
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.
Petersen FB; Appelbaum FR; Bigelow CL; Buckner CD; Clift RA; Sanders JE; Storb R; Sullivan KM; Weiden PL; Fefer A
Bone Marrow Transplant; 1989 Sep; 4(5):483-8. PubMed ID: 2676043
[TBL] [Abstract][Full Text] [Related]
17. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
[TBL] [Abstract][Full Text] [Related]
18. Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma.
Amadori S; Papa G; Avvisati G; Petti MC; Motta M; Salvagnini M; Meloni G; Martelli M; Monarca B; Mandelli F
J Clin Oncol; 1984 Feb; 2(2):98-101. PubMed ID: 6366149
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma.
Rohatiner A; Slevin ML; Dhaliwal HS; Malpas JS; Lister TA
Cancer Chemother Pharmacol; 1984; 12(2):90-3. PubMed ID: 6697429
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytosine arabinoside therapy for refractory leukemia.
Herzig RH; Wolff SN; Lazarus HM; Phillips GL; Karanes C; Herzig GP
Blood; 1983 Aug; 62(2):361-9. PubMed ID: 6223674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
